Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients | Zendy

Carrie C. Lubitz | Zendy; Konstantinos P. Economopoulos | Zendy; Stephen Sy | Zendy; Colden Johanson | Zendy; Heike Künzel | Zendy; Martín Reincke | Zendy; G. Scott Gazelle | Zendy; Milton C. Weinstein | Zendy; Thomas A. Gaziano | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients

Author(s) -

Carrie C. Lubitz,

Konstantinos P. Economopoulos,

Stephen Sy,

Colden Johanson,

Heike Künzel,

Martín Reincke,

G. Scott Gazelle,

Milton C. Weinstein,

Thomas A. Gaziano

Publication year - 2015

Publication title -

circulation cardiovascular quality and outcomes

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.692

H-Index - 87

eISSN - 1941-7705

pISSN - 1941-7713

DOI - 10.1161/circoutcomes.115.002002

Subject(s) - medicine , primary aldosteronism , cost effectiveness , blood pressure , population , quality adjusted life year , pediatrics , risk analysis (engineering) , environmental health

Primary aldosteronism (PA) is a common and underdiagnosed disease with significant morbidity potentially cured by surgery. We aim to assess if the long-term cardiovascular benefits of identifying and treating surgically correctable PA outweigh the upfront increased costs in patients at the time patients are diagnosed with resistant hypertension (RH).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research